EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden

Anders Gülfe, Johan K Wallman, Lars Erik Kristensen

7 Citationer (Scopus)
49 Downloads (Pure)

Fingeraftryk

Dyk ned i forskningsemnerne om 'EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden'. Sammen danner de et unikt fingeraftryk.

Medicin og biovidenskab